DLA Piper has advised on the sale of Pharmazeutische Fabrik Evers GmbH & Co KG to the Chinese company Bright Future Pharmaceutical Laboratories Ltd. The company mainly produces natural health products for the urology and gastroenterology sectors, which are sold internationally with a strong presence in the Asian market, primarily Japan and China. The parties agreed not to disclose the purchase price.

The family-owned Pharmazeutische Fabrik Evers GmbH & Co. KG was founded in 1933. The company, headquartered in Pinneberg near Hamburg, focusses on a selected range of natural health products for the urology and gastroenterology sectors, and acts as licensor in several countries. The brands Eviprostat S, Eviprostat N and Gallith are among the established products in this sector.

Established in 1993, Bright Future Pharmaceutical Laboratories Ltd is the largest GMP certified pharmaceutical manufacturer in Hong Kong. The company, with more than 7,000 employees, provides accessible and affordable medicines and is especially present in key growth markets including Hong Kong, Mainland China, North America, Africa, South-east Asia and Europe.

The transaction underlines once more the extensive experience of DLA Piper’s German China Desk, this time acting on the German sell-side.

The Hamburg-based DLA Piper Corporate team was led by partner Dr Nils Krause, supported by senior associate Dr Jan-Philipp Meier, as well as associates Dr Jasper von Georg and Ronja Hecker. Cologne-based Litigation and Regulatory partner Guido Kleve and counsel Dr Thilo Streit assisted the team, alongside Frankfurt-based Real Estate counsel Christian Lonquich and Corporate transaction lawyer Hui Hao based in Hamburg.